New Biogen CEO tips subcutaneous lecanemab to help expansion into pre-symptomatic Alzheimer’s

cafead

Administrator
Staff member
  • cafead   Jan 13, 2023 at 11:02: AM
via New Biogen CEO Chris Viehbacher has set out plans for a subcutaneous version of lecanemab, outlining how changing the delivery method of the Eisai-partnered Alzheimer’s disease drug could be particularly valuable for pre-symptomatic patients.

article source